Please login to the form below

Not currently logged in


This page shows the latest Zulresso news and features for those working in and with pharma, biotech and healthcare.

Sage slides off a MOUNTAIN as depression drug flunks trial

Sage slides off a MOUNTAIN as depression drug flunks trial

SAGE-217 is an oral follow-up to Sage’s  Zulresso (brexanolone) for postpartum depression (PPD), which was approved by the FDA in March and is delivered by a ... With analysts suggesting that Zulresso’s high cost ($34, 000 at US list price) and

Latest news

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...